Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
RALEIGH, N.C. and WELLESLEY HILLS, Mass., Feb. 12 /PRNewswire/ -- DARA BioSciences, Inc. ("DARA") and Point Therapeutics, Inc. ("Point") (NASDAQ:POTP) announced the consummation of their merger...
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that it has received proxies sufficient to approve the pending merger transaction with DARA BioSciences, Inc. and certain...
RALEIGH, N.C., Feb. 4 /PRNewswire/ -- DARA BioSciences, Inc. today announced that the Company will present at the ROTH 20th Annual Growth Stock Conference in Dana Point, CA on Tuesday, February...
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that it has adjourned its annual meeting of stockholders, which commenced at 10 a.m. this morning, until Tuesday...
Point Therapeutics, Inc. (NASDAQ: POTP) announced today that, as anticipated, Point received an additional notice of non-compliance from the staff of the Listing Qualifications...
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that the Securities and Exchange Commission has declared effective its Form S-4 Registration Statement, which contains a...
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that the NASDAQ Listing Qualifications Panel (the ?Panel?) has granted Point?s request for the continued listing of its...
RALEIGH, N.C., Oct. 25 /PRNewswire/ -- DARA BioSciences announced that current Director, President and CEO Richard A. Franco, Sr. has been appointed Chairman of the Board of Directors. The...
RALEIGH, N.C. and WEST HAVEN, Conn., Oct. 17 /PRNewswire/ -- DARA BioSciences, Inc. and Bayer Pharmaceuticals Corporation (BPC), a U.S. subsidiary of Bayer HealthCare AG signed a license...
Point Therapeutics, Inc. (NASDAQ: POTP) today reported financial results for the fiscal quarter and six months ended June 30, 2007. Point reported a net loss of $3,282,000...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
